Results for ondansetron translation from Maltese to English

ondansetron
ondansetron

dexamethasone ondansetron
dexamethasone ondansetron

ondansetron kliniċi:
ondansetron

ondansetron 4 mg iv (n=526)
ondansetron 4 mg iv (n=526)

ondansetron 4 mg fil-vini (n=526)
4 mg intravenously (n=526)

‘antagonist ta’ 5-ht3’ – bħal ondansetron
a corticosteroid - such as dexamethasone and a ‘5-ht3 antagonist’ - such as ondansetron

fil-ponv, emend kien effikaċi daqs ondansetron.
in ponv, emend was as effective as ondansetron.

150) tat-tfal li ngħataw ondansetron waħdu.
150) of children given ondansetron alone.

ondansetron aloxi 32 milligramma 250 mikrogramma (n= 185)
ondansetron

ondansetron (jintużaw għall-kura tad-dardir u rimettar)
ondansetron (used to treat nausea and vomiting)

§ differenza (%) kkalkulata bħala aprepitant 40 mg nieqes ondansetron 4 mg
§ difference (%) calculated as aprepitant 40 mg minus ondansetron 4 mg

għalhekk, l-użu ta’ ondansetron ma’ vandetanib mhuwiex rakkomandat.
therefore, the concomitant use of ondansetron with vandetanib is not recommended.

l-inkompatibilità fiżika kienet irrappurtata b’verapamil, ondansetron u ranitidine.
physical incompatibility has been reported with verapamil, ondansetron and ranitidine.

ondansetron għall-prevenzjoni tan-nawsja u tar-rimettar waqt il-kemoterapija
ondansetron to prevent nausea and vomiting during chemotherapy

l-użu ta’ vandetanib ma’ ondansetron mhux rakkomandat (ara sezzjoni 4.5).
the concomitant use of vandetanib with ondansetron is not recommended (see section 4.5)

ondansetron kien amministrat fil- vina 30 minuta qabel it- trattament bil- kimoterapija f’ jum 1.
ondansetron was administered intravenously 30 minutes prior to chemotherapy treatment on day 1.

il- pazjenti ġew maqsumin sabiex b' mod każwali jingħataw 40 mg aprepitant, 125 mg 6 aprepitant, jew 4 mg ondansetron.
patients were randomized to receive 40 mg aprepitant, 125 mg aprepitant, or 4 mg ondansetron.

fi studji kliniċi kkontrollati, li saru f' pazjenti li kienu qed jirċievu anestesija ġenerali, 564 pazjent ingħataw 40 mg aprepitant mill- ħalq u 538 pazjent ingħataw 4 mg ondansetron iv.
in controlled clinical studies in patients receiving general anesthesia, 564 patients were administered 40 mg aprepitant orally and 538 patients were administered 4 mg ondansetron iv.

ir- reazzjonijiet avversi li ġejjin ġew osservati f' pazjenti ttrattati b' aprepitant u f' inċidenza akbar minn dik b' ondansetron:
the following adverse reactions were observed in patients treated with aprepitant and at a greater incidence than with ondansetron:

fi studju li sar fuq pazjenti, il- ko - amministrazzjoni ta ’ granisetron, ondansetron, morphine jew kortikosterojdi ma jidhirx li kellhom effetti sinifikant fuq il- farmakokinetika ta ’ topotecan totali (fil- forma attiva jew inattiva).
in a population study, the co- 16 administration of granisetron, ondansetron, morphine or corticosteroids did not appear to have a significant effect on the pharmacokinetics of total topotecan (active and inactive form).